Calithera Biosciences, Inc

(NASDAQ:CALA)

Latest On Calithera Biosciences, Inc (CALA):

Date/Time Type Description Signal Details
2023-05-19 22:14 ESTNewsCalithera Biosciences plans special meeting to seek approval for liquidation and dissolution planN/A
2022-11-14 23:39 ESTNewsCalithera Biosciences reports Q3 resultsN/A
2022-11-14 23:38 ESTNewsCalithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call TranscriptN/A
2022-11-14 06:28 ESTNewsCalithera Biosciences Q3 2022 Earnings PreviewN/A
2022-10-03 09:11 ESTNewsCalithera gains 16% as FDA awards Fast Track status for lung cancer candidateN/A
2022-08-30 02:12 ESTNewsCalithera rises 8% after HC Wainwright upgrades rating to buyN/A
2022-08-16 05:22 ESTNewsCalithera Biosciences reports Q2 resultsN/A
2022-08-16 05:22 ESTNewsCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call TranscriptN/A
2022-06-14 13:36 ESTNewsCalithera Biosciences announces 1-for-20 reverse stock split to regain listing complianceN/A
2022-05-11 20:35 ESTNewsCalithera Biosciences stock slips after PT cut at LadenburgN/A
2022-05-11 01:15 ESTNewsCalithera Biosciences GAAP EPS of -$0.18 in-lineN/A
2022-05-11 01:15 ESTNewsCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-10 03:11 ESTNewsCalithera Biosciences Q1 2022 Earnings PreviewN/A
2022-04-03 23:30 ESTNewsCalithera Biosciences (CALA) Investor Presentation - SlideshowN/A
2022-04-01 20:20 ESTNewsCalithera stock falls 11% as Q4 net loss widens Y/YN/A
2022-04-01 03:48 ESTNewsCalithera Biosciences GAAP EPS of -$0.92 misses by $0.69N/A
2022-04-01 03:48 ESTNewsCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-31 08:00 ESTNewsCalithera Biosciences Q4 2021 Earnings PreviewN/A
2022-03-30 15:34 ESTNewsCalithera Biosciences slumps on pricing $10.0M stock and warrants offeringN/A
2022-03-29 23:00 ESTNewsCalithera Biosciences stock slides on stock and warrant offeringN/A
2021-11-12 18:07 ESTNewsWarning: CALA is at high risk of performing badlyN/A
2021-11-10 04:09 ESTNewsCalithera Biosciences EPS beats by $0.08N/A
2021-11-10 04:08 ESTNewsCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-09 05:10 ESTNewsCalithera Biosciences Q3 2021 Earnings PreviewN/A
2021-11-05 22:31 ESTNewsCalithera shares slump 33% after pulling plug on mid-stage telaglenastat lung cancer trialN/A
2021-11-01 16:25 ESTNewsCalithera shares early-stage data for cystic fibrosis candidateN/A
2021-10-19 06:51 ESTNewsCalithera to acquire 2 drug compounds from Takeda in cash-stock dealN/A
2021-08-08 09:26 ESTNewsCalithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-06 20:29 ESTNewsCalithera Biosciences (CALA) releases investors presentationN/A
2021-08-03 08:30 ESTNewsThe Upcoming Calithera Cystic Fibrosis Data Could Be SignificantN/A
2021-03-17 20:20 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 12:17 ESTEarnings EstimateAn EPS average of -$0.80 is estimated for the 2022 year.Sell
2021-03-17 12:17 ESTEarnings EstimateAn EPS average of -$0.25 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-16 20:55 ESTNewsCalithera Biosciences EPS in-lineN/A
2021-03-16 20:55 ESTNewsCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2020 Results - Earnings Call TranscriptN/A
2021-01-07 11:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $6 to $5.Neutral
2021-01-06 11:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $7.1 to $6.Neutral
2021-01-05 11:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.1 to $7.1.Neutral
2021-01-04 22:11 ESTNewsCalithera sinks as telaglenastat fails in kidney cancer study; lowers headcountN/A
2020-12-13 03:25 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 19:29 ESTNewsCalithera Biosciences Poised For Long-Term SuccessN/A
2020-11-15 11:31 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 19:23 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 03:22 ESTNewsCalithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-06 11:19 ESTEarnings EstimateAn EPS average of -$0.34 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-06 04:03 ESTNewsCalithera Biosciences EPS misses by $0.01N/A
2020-11-01 17:26 ESTFinancialsCompany financials have been released.Neutral
2020-09-28 19:56 ESTNewsCalithera Lung Cancer Trial, And Other News: The Good, Bad And Ugly Of BiopharmaN/A
2020-09-25 14:14 ESTNewsCalithera launches mid-stage study of telaglenstat in lung cancerN/A
2020-09-24 00:21 ESTFinancialsCompany financials have been released.Neutral

About Calithera Biosciences, Inc (CALA):

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

CALA Quotes by TradingView

See Advanced Chart

General

  • Name Calithera Biosciences, Inc
  • Symbol CALA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Last Split Factor1:48
  • Last Split Date2014-09-19
  • Fiscal Year EndDecember
  • IPO Date2014-10-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.calithera.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 1.73
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.95
  • Next Year EPS Estimate -$0.95
  • Next Quarter EPS Estimate -$0.29
  • Return on Assets -39%
  • Return on Equity -74%
  • Earnings Per Share -$2.23
  • Revenue Per Share $0
  • Gross Profit -71015000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 200.89 million
  • EBITDA -88539000
  • PEG Ratio -0.29
  • Analyst Target Price $5
  • Book Value Per Share $1.45
View More

Share Statistics

  • Shares Outstanding 73.32 million
  • Shares Float 63.91 million
  • % Held by Insiders 72%
  • % Held by Institutions 81.73%
  • Shares Short 2.53 million
  • Shares Short Prior Month 3 million
  • Short Ratio 1.97
  • Short % of Float 6%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 1.72
  • 52 Week High $8.18
  • 52 Week Low $2.6
  • 50 Day Moving Average 2.98
  • 200 Day Moving Average 3.74
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Calithera Biosciences, Inc (CALA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Calithera Biosciences, Inc (CALA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-17$N/A-$0.32-$0.320%
2020-09-302020-11-05$N/A-$0.32-$0.31-1.72%
2020-06-302020-08-10$N/A-$0.29-$0.3312.01%
2020-03-312020-05-07$N/A-$0.38-$0.36-5.76%
2019-12-312020-03-11$N/A-$0.39-$0.37-4.84%
2019-09-302019-11-12$N/A-$0.38-$0.4514.89%
2019-06-302019-08-08$N/A-$0.58-$0.56-4.35%
2019-03-312019-05-09$N/A-$0.61-$0.44-37.2%
2018-12-312019-03-07$22.25 million-$0.51-$0.47-7.87%
2018-09-302018-11-07$-17065000-$0.52-$0.40-30.46%
2018-06-302018-08-07$17.07 million-$0.09-$0.3271.87%
2018-03-312018-05-10$5.19 million-$0.37-$0.32-14.27%
2017-12-312018-03-08$7.25 million-$0.31-$0.22-41.36%
2017-09-302017-11-02$7.25 million-$0.17-$0.2221.7%
2017-06-302017-08-08$7.26 million-$0.15-$0.2231.35%
2017-03-312017-05-09$4.19 million-$0.22-$0.2923.77%
2016-12-312017-03-16$N/A-$0.45-$0.461.96%
2016-09-302016-11-09$N/A-$0.44-$0.5215.21%
2016-06-302016-08-09$N/A-$0.55-$0.52-5.77%
2016-03-312016-05-10$N/A-$0.52-$0.47-9.87%
2015-12-312016-03-15$N/A-$0.44-$0.5621.43%
2015-09-302015-11-09$50000-$0.49-$0.525.77%
2015-06-302015-08-10$56000-$0.44-$0.440%
2015-03-312015-05-07$9000-$0.44-$0.476.38%
2014-12-312015-03-26$N/A-$0.39-$0.4717.02%
2014-09-302014-11-14$2000-$16.85-$0.35-4714.29%

Calithera Biosciences, Inc (CALA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A 20.13 million N/A
Income Before Tax N/A N/A N/A -24.45 million -21.73 million
Selling General Administrative N/A N/A N/A 4.95 million 4.55 million
Gross Profit N/A N/A N/A N/A -17.9 million
Ebit N/A -22.82 million N/A -24.97 million -22.45 million
Operating Income N/A N/A N/A -25.07 million -22.45 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A 17.9 million
Total Other Income Expense Net N/A N/A N/A N/A 725000
Net Income From Continuing Operations N/A N/A N/A -24.45 million -21.73 million
Net Income Applicable to Common Shares -22.57 million -22.73 million -20.39 million -24.45 million -21.73 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A 58.52 million N/A 15.15 million -35.2 million
Change to Liabilities 1.9 million -62000 -1.32 million 1.35 million -546000
Total Cash Flow from Investing Activities 21.99 million 58.52 million -614000 15.15 million -35.21 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 2000 33.9 million N/A 42.02 million -247000
Change to Operating Activities 1.49 million -49000 -3.13 million -1.01 million -571000
Change in Cash 5.69 million 74.43 million N/A 38.78 million -55.13 million
Total Cash from Operating Activities -16.3 million -18 million -27.02 million -18.4 million -19.68 million
Depreciation N/A 91000 N/A 113000 116000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables 457000 53000 N/A 1.23 million 28000
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 2.5 million 2.36 million 2.27 million 1.65 million 1.59 million
Capital Expenditures N/A N/A N/A 1000 8000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A 22.01 million 26.34 million
Total Stockholder Equity N/A N/A N/A 127.67 million 142.43 million
Other Current Liabilities N/A N/A N/A 1.29 million 1.55 million
Total Assets N/A N/A N/A 149.68 million 168.77 million
Common Stock 7000 7000 7000 6000 6000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -376.24 million -353.67 million -330.94 million -310.55 million -286.1 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 440000 784000 1.04 million 998000 720000
Cash N/A N/A N/A 40.47 million 60.44 million
Total Current Liabilities 18.4 million 19.8 million N/A 15.75 million 19.62 million
Other Stockholder Equity 3000 46000 117000 75000 42000
Property, Plant & Equipment 6.44 million 6.89 million 7.33 million 7.8 million 8.25 million
Total Current Assets 118.7 million 140.04 million N/A 137.88 million 159.8 million
Long Term Investments N/A N/A N/A 3.01 million N/A
Net Tangible Assets 102.37 million 122.6 million 143.28 million 127.67 million 142.43 million
Short Term Investments N/A N/A N/A 94.64 million 96.92 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.99 million 2.64 million N/A 739000 2.05 million

Calithera Biosciences, Inc (CALA) Chart:

Calithera Biosciences, Inc (CALA) News:

Below you will find a list of latest news for Calithera Biosciences, Inc (CALA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Calithera Biosciences, Inc (CALA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest CALA Trades:

Date Shares Price
Jun 13, 2022 7:45 PM EST100$0.2001
Jun 13, 2022 7:45 PM EST300$0.2001
Jun 13, 2022 7:45 PM EST1900$0.2001
Jun 13, 2022 7:47 PM EST44$0.2001
Jun 13, 2022 7:56 PM EST700$0.2031

Calithera Biosciences, Inc (CALA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520167673/0001193125-20-167673-index.htm
2020-08-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1496671/000000000020007528/0000000000-20-007528-index.htm
2019-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000021545719003074/0000215457-19-003074-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000083423720004597/0000834237-20-004597-index.htm
2020-03-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000089914020000214/0000899140-20-000214-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318006476/0000899243-18-006476-index.htm
2018-04-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318009562/0000899243-18-009562-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318014881/0000899243-18-014881-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318014882/0000899243-18-014882-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318014883/0000899243-18-014883-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318014884/0000899243-18-014884-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318014885/0000899243-18-014885-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318014887/0000899243-18-014887-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318014889/0000899243-18-014889-index.htm
2018-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318026572/0000899243-18-026572-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318026708/0000899243-18-026708-index.htm
2018-10-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318026882/0000899243-18-026882-index.htm
2018-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318029125/0000899243-18-029125-index.htm
2018-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924318029127/0000899243-18-029127-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319001124/0000899243-19-001124-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319001126/0000899243-19-001126-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319001128/0000899243-19-001128-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319001131/0000899243-19-001131-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319001133/0000899243-19-001133-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319001134/0000899243-19-001134-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319001135/0000899243-19-001135-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319001137/0000899243-19-001137-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319003138/0000899243-19-003138-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319003139/0000899243-19-003139-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319007526/0000899243-19-007526-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319008333/0000899243-19-008333-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319010747/0000899243-19-010747-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319014707/0000899243-19-014707-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319015379/0000899243-19-015379-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319015380/0000899243-19-015380-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319015381/0000899243-19-015381-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319015382/0000899243-19-015382-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319015383/0000899243-19-015383-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319015384/0000899243-19-015384-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319015385/0000899243-19-015385-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319017412/0000899243-19-017412-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319017415/0000899243-19-017415-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319017790/0000899243-19-017790-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319018201/0000899243-19-018201-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319018344/0000899243-19-018344-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319018345/0000899243-19-018345-index.htm
2019-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924319030045/0000899243-19-030045-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320001664/0000899243-20-001664-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320001671/0000899243-20-001671-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320001672/0000899243-20-001672-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320001687/0000899243-20-001687-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320001690/0000899243-20-001690-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320001693/0000899243-20-001693-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320001694/0000899243-20-001694-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320001696/0000899243-20-001696-index.htm
2020-02-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320005595/0000899243-20-005595-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320010902/0000899243-20-010902-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320016146/0000899243-20-016146-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320016148/0000899243-20-016148-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320016149/0000899243-20-016149-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320016150/0000899243-20-016150-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320016151/0000899243-20-016151-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320016152/0000899243-20-016152-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320016153/0000899243-20-016153-index.htm
2020-07-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320019073/0000899243-20-019073-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000089924320021137/0000899243-20-021137-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000090221919000100/0000902219-19-000100-index.htm
2019-11-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000090221919000462/0000902219-19-000462-index.htm
2018-09-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000092189518002533/0000921895-18-002533-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000092189519000477/0000921895-19-000477-index.htm
2019-06-25SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000092189519001892/0000921895-19-001892-index.htm
2019-07-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000092189519001943/0000921895-19-001943-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000092189519002646/0000921895-19-002646-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000092189519002818/0000921895-19-002818-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000092189519002868/0000921895-19-002868-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000092189520000526/0000921895-20-000526-index.htm
2020-05-26SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000092189520001600/0000921895-20-001600-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1496671/000092189520001604/0000921895-20-001604-index.htm
2020-01-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000110465920002903/0001104659-20-002903-index.htm
2020-02-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1496671/000110465920012198/0001104659-20-012198-index.htm
2020-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000110465920113552/0001104659-20-113552-index.htm
2018-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312518075126/0001193125-18-075126-index.htm
2018-03-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1496671/000119312518075349/0001193125-18-075349-index.htm
2018-04-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1496671/000119312518113086/0001193125-18-113086-index.htm
2018-04-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1496671/000119312518113103/0001193125-18-113103-index.htm
2018-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312518159232/0001193125-18-159232-index.htm
2018-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312518184437/0001193125-18-184437-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312518241212/0001193125-18-241212-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312518320984/0001193125-18-320984-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519003756/0001193125-19-003756-index.htm
2019-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519008962/0001193125-19-008962-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519067185/0001193125-19-067185-index.htm
2019-03-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1496671/000119312519067284/0001193125-19-067284-index.htm
2019-04-05DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1496671/000119312519099187/0001193125-19-099187-index.htm
2019-04-05DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1496671/000119312519099209/0001193125-19-099209-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519143079/0001193125-19-143079-index.htm
2019-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519164094/0001193125-19-164094-index.htm
2019-06-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1496671/000119312519174849/0001193125-19-174849-index.htm
2019-06-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1496671/000119312519176538/0001193125-19-176538-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519176545/0001193125-19-176545-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519216822/0001193125-19-216822-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519289961/0001193125-19-289961-index.htm
2019-12-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1496671/000119312519308385/0001193125-19-308385-index.htm
2019-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312519308391/0001193125-19-308391-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520005892/0001193125-20-005892-index.htm
2020-01-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520009031/0001193125-20-009031-index.htm
2020-03-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1496671/000119312520070381/0001193125-20-070381-index.htm
2020-03-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1496671/000119312520070400/0001193125-20-070400-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520070405/0001193125-20-070405-index.htm
2020-04-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1496671/000119312520108089/0001193125-20-108089-index.htm
2020-04-16424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1496671/000119312520109296/0001193125-20-109296-index.htm
2020-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520109344/0001193125-20-109344-index.htm
2020-04-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1496671/000119312520113592/0001193125-20-113592-index.htm
2020-04-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1496671/000119312520113604/0001193125-20-113604-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520136249/0001193125-20-136249-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520167673/0001193125-20-167673-index.htm
2020-07-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520192285/0001193125-20-192285-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520214897/0001193125-20-214897-index.htm
2020-08-10S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1496671/000119312520214988/0001193125-20-214988-index.htm
2020-08-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1496671/000119312520222405/0001193125-20-222405-index.htm
2020-08-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1496671/000119312520224706/0001193125-20-224706-index.htm
2020-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520239036/0001193125-20-239036-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1496671/000119312520286832/0001193125-20-286832-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1496671/000156459018004953/0001564590-18-004953-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459018012967/0001564590-18-012967-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459018019999/0001564590-18-019999-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459018028126/0001564590-18-028126-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1496671/000156459019006798/0001564590-19-006798-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459019018087/0001564590-19-018087-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459019030797/0001564590-19-030797-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459019042964/0001564590-19-042964-index.htm
2020-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1496671/000156459020010058/0001564590-20-010058-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459020022918/0001564590-20-022918-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459020038904/0001564590-20-038904-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1496671/000156459020051364/0001564590-20-051364-index.htm
2019-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000162363219000240/0001623632-19-000240-index.htm
2019-05-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000162363219000633/0001623632-19-000633-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1496671/000162363220000258/0001623632-20-000258-index.htm
2020-08-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1496671/999999999520002203/9999999995-20-002203-index.htm
2018-05-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1496671/999999999718005347/9999999997-18-005347-index.htm
2018-05-10CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1496671/999999999718005651/9999999997-18-005651-index.htm

Calithera Biosciences, Inc (CALA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Calithera Biosciences, Inc (CALA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 72%
Institutional Ownership: 8173%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-05-22Keith OrfordChief Medical OfficerSell416.006.002,496.0010,000.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319014707/0000899243-19-014707-index.htm
2018-10-15Keith OrfordSR. VP, CLINICAL DEVELOPMENTSell313.006.051,893.6510,314.00https://www.sec.gov/Archives/edgar/data/1496671/000089924318026882/0000899243-18-026882-index.htm
2019-04-15Keith OrfordChief Medical OfficerSell416.006.332,633.2810,416.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319010747/0000899243-19-010747-index.htm
2018-10-11Keith OrfordSR. VP, CLINICAL DEVELOPMENTSell1,252.006.007,512.0010,627.00https://www.sec.gov/Archives/edgar/data/1496671/000089924318026708/0000899243-18-026708-index.htm
2019-03-15Keith OrfordChief Medical OfficerSell417.006.432,681.3110,832.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319008333/0000899243-19-008333-index.htm
2019-03-11Keith OrfordChief Medical OfficerSell1,565.006.009,390.0011,249.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319007526/0000899243-19-007526-index.htm
2019-12-23Keith OrfordChief Medical OfficerSell3,021.006.0018,126.0011,562.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319030045/0000899243-19-030045-index.htm
2019-06-17Keith OrfordChief Medical OfficerSell417.006.002,502.0012,083.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319017412/0000899243-19-017412-index.htm
2020-05-21PARTNERS L P/IL BVF10% Share HolderSell1,064,332.006.006,385,992.002,766,561.00https://www.sec.gov/Archives/edgar/data/1496671/000092189520001604/0000921895-20-001604-index.htm
2020-04-15Stephanie WongSR. VP, FINANCE & SECRETARYSell5,000.008.0040,000.0030,082.00https://www.sec.gov/Archives/edgar/data/1496671/000089924320010902/0000899243-20-010902-index.htm
2019-06-19Stephanie WongSR. VP, FINANCE & SECRETARYBuy10,000.002.6426,400.0031,751.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319017790/0000899243-19-017790-index.htm
2019-10-29PARTNERS L P/IL BVF10% Share HolderBuy610,052.002.601,586,135.203,374,672.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002646/0000921895-19-002646-index.htm
2019-10-30PARTNERS L P/IL BVF10% Share HolderBuy331,048.002.70893,829.603,705,720.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002646/0000921895-19-002646-index.htm
2020-05-21PARTNERS L P/IL BVF10% Share HolderSell1,027,016.006.006,162,096.003,712,340.00https://www.sec.gov/Archives/edgar/data/1496671/000092189520001604/0000921895-20-001604-index.htm
2019-11-14PARTNERS L P/IL BVF10% Share HolderBuy45,888.003.37154,642.563,751,608.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002818/0000921895-19-002818-index.htm
2019-11-20PARTNERS L P/IL BVF10% Share HolderBuy79,285.003.91310,131.213,830,893.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002868/0000921895-19-002868-index.htm
2019-10-29PARTNERS L P/IL BVF10% Share HolderBuy872,373.002.602,268,169.804,160,751.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002646/0000921895-19-002646-index.htm
2019-06-17Francesco ParlatiVP, RESEARCHBuy6,246.002.6416,489.4442,201.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319017415/0000899243-19-017415-index.htm
2018-04-03Eric SjogrenSR. VP, DRUG DISCOVERYBuy16,810.000.488,068.8042,818.00https://www.sec.gov/Archives/edgar/data/1496671/000089924318009562/0000899243-18-009562-index.htm
2018-03-02Susan MolineauxPRESIDENT AND CEOBuy26,992.002.6471,258.8844,860.00https://www.sec.gov/Archives/edgar/data/1496671/000089924318006476/0000899243-18-006476-index.htm
2019-10-30PARTNERS L P/IL BVF10% Share HolderBuy408,592.002.701,103,198.404,569,343.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002646/0000921895-19-002646-index.htm
2019-06-25Christopher MolineauxSR. VP, DEVELOPMENTBuy51,600.003.88200,208.00457,188.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319018345/0000899243-19-018345-index.htm
2019-06-25Susan MolineauxPRESIDENT AND CEOBuy51,600.003.88200,208.00457,188.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319018344/0000899243-19-018344-index.htm
2019-11-14PARTNERS L P/IL BVF10% Share HolderBuy71,495.003.37240,938.154,640,838.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002818/0000921895-19-002818-index.htm
2019-11-20PARTNERS L P/IL BVF10% Share HolderBuy98,518.003.91385,363.014,739,356.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002868/0000921895-19-002868-index.htm
2020-05-21PARTNERS L P/IL BVF10% Share HolderSell192,250.006.001,153,500.00480,432.00https://www.sec.gov/Archives/edgar/data/1496671/000092189520001604/0000921895-20-001604-index.htm
2019-10-29PARTNERS L P/IL BVF10% Share HolderBuy116,552.002.60303,035.20589,558.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002646/0000921895-19-002646-index.htm
2019-10-30PARTNERS L P/IL BVF10% Share HolderBuy57,868.002.70156,243.60647,426.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002646/0000921895-19-002646-index.htm
2019-11-14PARTNERS L P/IL BVF10% Share HolderBuy11,105.003.3737,423.85658,531.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002818/0000921895-19-002818-index.htm
2019-11-20PARTNERS L P/IL BVF10% Share HolderBuy14,151.003.9155,353.05672,682.00https://www.sec.gov/Archives/edgar/data/1496671/000092189519002868/0000921895-19-002868-index.htm
2019-06-24Eric SjogrenSR. VP, DRUG DISCOVERYBuy21,739.000.9620,869.4472,057.00https://www.sec.gov/Archives/edgar/data/1496671/000089924319018201/0000899243-19-018201-index.htm
2020-02-20Keith OrfordChief Medical OfficerSell3,021.008.0024,168.008,541.00https://www.sec.gov/Archives/edgar/data/1496671/000089924320005595/0000899243-20-005595-index.htm